Table 1. Univariate survival analysis for clinicopathological data.
| variable | number of patients | dead | survival# | p value* |
|---|---|---|---|---|
| sex | ||||
| male | 40 (93.0%) | 23 (82.0%) | 18.7 (range 2.3–62.4) | 0.641 |
| female | 3 (7.0%) | 2 (8.0%) | 37.1 (range 19.1–62.1) | |
| T stage | ||||
| 1 | 9 (20.9%) | 2 (8.0%) | 37.3 (range 3.4–62.4) | 0.051 |
| 3 | 27 (62.8%) | 17 (68.0%) | 15.0 (range 2.3–51.7) | |
| 4 | 7 (16.3%) | 6 (24.0%) | 18.9 (range 3.8–62.1) | |
| N stage | ||||
| 0 | 11 (25.6%) | 5 (20.0%) | 18.8 (range 2.3–49.5) | 0.221 |
| 1 | 7 (16.3%) | 4 (16.0%) | 31.2 (range 4.0–62.1) | |
| 2 | 11 (25.6%) | 5 (20.0%) | 17.5 (range 4.3–62.4) | |
| 3 | 14 (32.6%) | 11 (44.0%) | 16.8 (range 3.8–48.4) | |
| M stage | ||||
| 0 | 36 (83.7%) | 19 (76.0%) | 19.1 (range 2.3–62.4) | 0.005 |
| 1 | 7 (16.3%) | 6 (24.0%) | 11.5 (range 3.8–22.9) | |
| UICC | ||||
| I | 6 (14.0%) | 0 (0.0%) | 18.8 (range 3.4–49.5) | 0.007 |
| II | 7 (16.3%) | 6 (24.0%) | 28.1 (range 2.3–43.1) | |
| III | 23 (53.5%) | 13 (52.0%) | 20.4 (range 4.0–62.4) | |
| IV | 7 (16.3%) | 6 (24.0%) | 11.5 (range 3.8–22.9) | |
| R status | ||||
| 0 | 30 (69.8%) | 14 (56.0%) | 20.4 (range 3.4–62.4) | 0.005 |
| 1 | 13 (30.2%) | 11 (44.0%) | 13.4 (range 2.3–62.1) | |
| G status | ||||
| 1 | 3 (7.0%) | 0 (0.0%) | 37.3 (range 18.9–49.5) | 0.146 |
| 2 | 12 (27.9%) | 8 (32.0%) | 12.1 (range 3.4–51.7) | |
| 3 | 28 (65.1%) | 17 (68.0%) | 19.1 (range 2.3–62.4) |
T stage: describing the size and depth of tumor invasion; N stage: tumor involvement of nearby lymph nodes; M category: distant metastasis; UICC (Union for International Cancer Control): comprising the TNM categories; R: residual tumor at resection margins; G: grading of tumor cells.
* log-rank test
# patients who died within 30days after surgery were excluded. Survival time is presented in months. Significant p values (p<0.05) are highlighted in italic.